In a retrospective study where 10 patients with pancreatic NET G3 (median Ki‐67 35%) received sunitinib, disease control was reported in 9, with a PFS of approximately 6 months.34 The gene discussed is MKI67; the disease is pancreatic neuroendocrine tumor.